Search for: All records

Abstract The UltraViolet imaging of the Cosmic Assembly Near-infrared Deep Extragalactic Legacy Survey Fields (UVCANDELS) program provides Hubble Space Telescope (HST)/UVIS F275W imaging for four CANDELS fields. We combine this UV imaging with existing HST/near-IR grism spectroscopy from 3D-HST+AGHAST to directly compare the resolved rest-frame UV and H α emission for a sample of 979 galaxies at 0.7 < z < 1.5, spanning a range in stellar mass of 10 8−11.5 M ⊙ . Using a stacking analysis, we perform a resolved comparison between homogenized maps of rest-UV and H α to compute the average UV-to-H α luminosity ratio (an indicator of burstiness in star formation) as a function of galactocentric radius. We find that galaxies below stellar mass of ∼10 9.5 M ⊙ , at all radii, have a UV-to-H α ratio higher than the equilibrium value expected from constant star formation, indicating a significant contribution from bursty star formation. Even for galaxies with stellar mass ≳10 9.5 M ⊙ , the UV-to-H α ratio is elevated toward their outskirts ( R / R eff > 1.5), suggesting that bursty star formation is likely prevalent in the outskirts of even the most massive galaxies, but is likely overshadowed by their brighter cores. Furthermore, we present the UV-to-H α ratio as a function of galaxy surface brightness, a proxy for stellar mass surface density, and find that regions below ∼10 7.5 M ⊙ kpc −2 are consistent with bursty star formation, regardless of their galaxy stellar mass, potentially suggesting that local star formation is independent of global galaxy properties at the smallest scales. Last, we find galaxies at z > 1.1 to have bursty star formation, regardless of radius or surface brightness. 

Abstract The identification of the Omicron (B.1.1.529.1 or BA.1) variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in Botswana in November 2021 1 immediately caused concern owing to the number of alterations in the spike glycoprotein that could lead to antibody evasion. We 2 and others 3–6 recently reported results confirming such a concern. Continuing surveillance of the evolution of Omicron has since revealed the rise in prevalence of two sublineages, BA.1 with an R346K alteration (BA.1+R346K, also known as BA.1.1) and B.1.1.529.2 (BA.2), with the latter containing 8 unique spike alterations and lacking 13 spike alterations found in BA.1. Here we extended our studies to include antigenic characterization of these new sublineages. Polyclonal sera from patients infected by wild-type SARS-CoV-2 or recipients of current mRNA vaccines showed a substantial loss in neutralizing activity against both BA.1+R346K and BA.2, with drops comparable to that already reported for BA.1 (refs. 2,3,5,6 ). These findings indicate that these three sublineages of Omicron are antigenically equidistant from the wild-type SARS-CoV-2 and thus similarly threaten the efficacies of current vaccines. BA.2 also exhibited marked resistance to 17 of 19 neutralizing monoclonal antibodies tested, including S309 (sotrovimab) 7 , which had retained appreciable activity against BA.1 and BA.1+R346K (refs. 2–4,6 ). This finding shows that no authorized monoclonal antibody therapy could adequately cover all sublineages of the Omicron variant, except for the recently authorized LY-CoV1404 (bebtelovimab).